Description: Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. It also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.
Home Page: www.ampliatx.com
350 Queen Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9123 1140
Officers
| Name | Title |
|---|---|
| Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | CEO, MD & Director |
| Mr. Timothy Luscombe B.Com., C.A. | Chief Financial Officer |
| Ms. Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer |
| Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3098 |
| Price-to-Sales TTM: | 4.7665 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |